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ABSTRACT
Background
Granulocyte transfusion has been proposed as a bridging therapy for patients with prolonged
periods of chemotherapy-induced neutropenia, who suffer from severe fungal and bacterial
infections. To recover, adequate numbers of granulocytes are required when the patients are
refractory to standard treatment. The aim of this study was to assess the functional character-
istics and efficacy of granulocyte colony-stimulating factor/dexamethasone-mobilized granulo-
cytes used for transfusions.
Design and Methods
Granulocytes from the leukapheresis products were tested for the expression of cell-surface
antigens, interactions with endothelial cells, motility, killing of microbes and survival. The gran-
ulocytes were used in vivo for transfusion in 16 severely ill children, who were – apart from a
patient with a granulocyte dysfunction – all suffering from prolonged neutropenia.
Results
Mobilization of granulocytes with granulocyte colony-stimulating factor and dexamethasone
caused phenotypic changes (decreased CD62L expression and increased levels of CD66b and
CD177). The ability of the granulocytes to interact with endothelial cells (rolling, adhesion,
transmigration) and to kill various types of pathogens was not affected by the mobilization,
leukapheresis and irradiation procedures. The granulocytes were functionally indistinguishable
from those isolated from untreated donors, even after 24 hours of storage. Granulocyte trans-
fusion seemed to benefit 70% of patients, as 11 out of the 16 children showed clinical recov-
ery within 1-2 weeks after beginning the transfusions.
Conclusions
Although CD62L expression is downregulated on granulocytes used for granulocyte transfu-
sions, concomitant CD177 upregulation may explain the intact interactions with endothelial
cells. All other granulocyte functions tested were intact, including the ability to kill fungi.
Granulocyte concentrates can be stored without loss of in vitro viability and functionality for at
least 24 hours. As demonstrated in vivo, granulocyte transfusions may be an effective therapy
for neutropenic pediatric patients suffering from life-threatening infections.
Key words: granulocytes, granulocyte colony-stimulating factor, phenotype, function, transfusion.
Citation: Drewniak A, Boelens J-J, Vrielink H, Tool ATJ, Bruin MCA, van den Heuvel-Eibrink M, Ball
L, van de Wetering MD, Roos D, and Kuijpers TW. Granulocyte concentrates: prolonged function-
al capacity during storage in the presence of phenotypic changes. Haematologica 2008;
93:1058-1067. doi: 10.3324/haematol.12489
©2008 Ferrata Storti Foundation. This is an open-access paper.
haematologica | 2008; 93(7) | 1059 |
Introduction
Patients with prolonged neutropenia after
chemotherapy are prone to serious bacterial and fungal
infections.1 Despite novel and appropriate antimicro-
bial therapies and the use of growth factors such as
granulocyte colony-stimulating factor (G-CSF), patients
may remain refractory to these therapies. To improve
the outcome of these patients, granulocyte transfusions
have been suggested as a promising therapy in addition
to antimicrobial therapy. Recent studies on the use of
recombinant G-CSF to mobilize bone-marrow granulo-
cytes to the blood pool in granulocyte donors have pro-
vided encouraging results.2-10 So far the most efficient
way to increase the level of neutrophils is to administer
a single dose of G-CSF plus corticosteroids11 to increase
the granulocyte yield 5- to 10-fold higher than a decade
ago; this ensures a good therapeutic dose of granulo-
cytes for transfusion. To provide effective therapy, not
only must the numbers of granulocytes be sufficient,
but the cells must also retain full functional capacity.
Mobilized granulocytes given to a patient must be
capable of reaching the sites of ongoing infection and
effectively fighting the invading pathogens.
Administration of G-CSF/dexamethasone to the donor
has been described to change the phenotype of mobi-
lized granulocytes, although their basic functions such
as oxidative burst and phagocytosis, remain unaffect-
ed.12-14 However, very little is known about the interac-
tion between granulocytes obtained from granulocyte
concentrates, used for transfusion, and endothelial cells
or about their capacity to kill bacterial and fungal
pathogens.
In this study, we first performed an extensive pheno-
typic and functional characterization of the granulo-
cytes from the leukapheresis product, obtained after in
vivo G-CSF/dexamethasone mobilization, focusing on
aspects relevant for fighting infections, such as rolling
over and adhesion to endothelial cells under flow con-
ditions, transmigration, chemotaxis, respiratory burst
and microbial killing. We also evaluated the effect of
storing the granulocyte concentrates on the functional
capacity of the cells. In addition, we followed the kinet-
ics of the granulocytes transfused, as well as the effica-
cy of the transfused product in vivo, in a group of pedi-
atric patients given pre-emptive or curative treatment
with granulocyte transfusions.
Design and Methods
Patients
Selection of the patients and treatment indications
Seventeen hemato-oncology and stem-cell transfu-
sion (SCT) patients and one patient with a primary
immunodeficiency disorder were selected either for
curative or pre-emptive treatment with granulocyte
transfusions. The patients were followed at the
Academic Medical Center (AMC) in Amsterdam,
Erasmus Medical Center (Erasmus MC) in Rotterdam,
Leiden University Medical Center (LUMC) in Leiden,
and the University Medical Center Utrecht (UMCU).
Patients with proven fungal or bacterial infection, unre-
sponsive to appropriate antimicrobial therapy or with
progressing infection at 72 hours after the initiation of
such therapy and with no neutrophil regeneration with
G-CSF, were selected for curative treatment with gran-
ulocyte transfusions in addition to anti-microbial ther-
apy. Those with poorly controlled fungal or bacterial
infections prior to allogeneic SCT (for any indication
and for whom a delay of the transplant was unaccept-
able) were selected for pre-emptive granulocyte trans-
fusions in addition to anti-microbial treatment. The
study was approved by the Ethics Committees of the
AMC Hospital, UMCU Hospital, LUMC Hospital and
Erasmus University Hospital and was conducted in
accordance with the Declaration of Helsinki.
Granulocyte transfusion and follow-up
Granulocytes were transfused three times a week.
The absolute neutrophil count (ANC) was measured 1
hour, 1 day and 2 days after each infusion. Patients
with neutropenia received G-CSF (10 µg/kg/day), as
did SCT recipients starting at day +7 after infusion of
the stem cell graft. 
Granulocytes were infused over 30 to 60 minutes,
within 6 hours of collection. In the case of ABO incom-
patibility, the granulocytes were infused in 3 hours. To
prevent allergic transfusion-related reactions in the
patients, clemastine (0.05 mg/kg) was administered
prior to the transfusion.
Granulocyte transfusions were stopped when the
infection was under control or when the ANC was
above 500/µL in the case of SCT patients receiving pre-
emptive treatment. In addition to the ANC, C-reactive
protein (CRP) and galactomannan (in cases of
Aspergillus infection) were used as parameters to meas-
ure infection control. Patients were closely monitored
for all transplantation-related morbidities, such as graft-
versus-host disease (GvHD). 
Donor procedures
Donor selection, mobilization and apheresis of granulocytes 
Granulocyte donors were selected from volunteers
among family members of the patients, based on the
general criteria for the selection of blood donors and
absence of contraindications to the administration of
G-CSF and/or dexamethasone. After informed consent,
the potential donor was medically assessed by a
trained, independent physician, and blood samples
were taken for virology tests (e.g. CMV, HBV, HCV,
HIV) and typing of ABO and Rhesus D (RhD) blood
groups. Preferably, ABO RhD-compatible (and in the
case of CMV-negative patients, CMV-negative) donors
were selected from the available donor pool. In the case
of ABO incompatibility, anti-A and/or B antibody titers
of ≤1:64 (in indirect antiglobulin tests) were accepted.
Approximately 12 hours prior to the leukapheresis
procedure, G-CSF (5 µg/kg, subcutaneously) and dex-
amethasone (8 mg, orally) were administered to the
donor. 
Leukapheresis procedures were performed with the
COBE Spectra® apheresis system (Gambro BCT,
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Lakewood, CO, USA) via a peripheral venous access
(dual needle), with application of the PMN program.
The product was collected into the PCV bags with the
anticoagulant consisting of 30 mL of 46.7% (w/v) sodi-
um citrate in 500 mL of 6% (w/v) hydroxyethyl starch
(HES) solution. The anticoagulant-starch to whole-
donor-blood volume ratio was set at 1:13. For pediatric
patients, the target number of granulocytes to be har-
vested was about 2.5×109/kg bodyweight of the
patient. In patients weighing more than 40 kg, the aim
was to obtain a product with as many neutrophils as
possible and more than 50×109 granulocytes per unit to
be transfused. Immediately after harvesting, the granu-
locyte concentrate was irradiated (25 Gy).
Granulocyte isolation
For the in vitro functional studies, granulocytes were
purified from the leukapheresis product or from
heparinized venous blood collected from healthy vol-
unteers or the granulocyte donors prior to the leuka-
pheresis. The granulocytes were isolated as described
previously .15,16
Immunophenotyping of granulocytes
Cell surface expression of various receptors on gran-
ulocytes was assayed in total leukocyte samples by
direct or two-step immunofluorescence flow cytome-
try (FACS), with saturating concentrations of commer-
cially available monoclonal antibodies, labeled with
either fluorescein isothiocyanate (FITC), phycoerythrin
(PE) or unconjugated, according to the manufacturer’s
procedure. CD11b-FITC, CD18-FITC, CD16-FITC,
CD64-FITC, CD66b-FITC and CD31 were from
Sanquin Reagents, Amsterdam, The Netherlands;
CD62L-PE and HLA-DR-PE were from BD
PharMingen, San Diego, CA, USA; CD177 was from
AbD Serotec, Oxford, UK; ICAM-2 (CD102) was from
Santa Cruz Biotechnology, Santa Cruz, CA, USA;
PSGL-1 (CD162) and CD63-FITC were from
Immunotech, Marseille, France; CD99 was from
Abcam, Cambridge, UK; goat F(ab’)2 anti-mouse-APC
was from Southern Biotech (Birmingham, AL, USA).
Cells were gated based on their forward and side scat-
ter properties, and 10 000 gated events were collected
per sample: 100% positive staining for CD16 and neg-
ative for CD36 (monocytes) or CD56 (NK cells) con-
firmed the purity of the analyzed population. 
Standard granulocyte chemotaxis and NADPH
oxidase activity
Chemotaxis was assessed by means of Fluoroblock
inserts (Falcon; Becton Dickinson, USA), as has been
described in detail elsewhere.17 NADPH-oxidase activi-
ty was assessed as the release of hydrogen peroxide,
determined by an Amplex Red kit (Molecular Probes,
Eugene, OR, USA) as described previously.18
Rolling over and adhesion to endothelial cells under
flow conditions 
Human umbilical vein endothelial cells (HUVEC)
were isolated from human umbilical cord veins. Cells
were cultured in RPMI-1640 medium containing 20%
(v/v) human serum, 100 U/mL penicillin and 100 µg/mL
streptomycin (Life Technologies, Paisley, UK) and
grown to confluence in 5-7 days. Primary endothelial
cells of the first or second passage were used in the
experiments. 19,20
HUVEC were first coated on glass cover slips, grown
until confluence (i.e. for approximately 2 days), and
then stimulated with tumor necrosis factor-α (100
U/mL; Boehringer Mannheim, Germany) for 6 hours
before starting perfusion. Granulocytes (2×106/mL)
were perfused over the HUVEC for 10 minutes at a
flow rate of 100 µL/min. During perfusion the flow
chamber was mounted on a microscope stage (Axiovert
25; Zeiss, Oberkochen, Germany) equipped with a
black-and-white charge-coupled device video camera
(Sanyo, Osaka, Japan) coupled to a VHS video recorder.
The number of adherent cells was evaluated using
image analysis software OPTIMAS 6. Cells that were
in contact with the surface appeared as bright white-
centered cells after adjustment of the microscope dur-
ing the recording.19,21
Transendothelial migration assay
Transmigration assays were performed with 6.5-mm
Transwells with 8-µm pore size (Costar, Cambridge,
MA, USA). Inserts were coated with 20 µg/mL
fibronectin (Sigma). HUVEC were seeded on the
Transwells 2 days prior to the assay and cultured in a
humidified atmosphere (37°C and 5% CO2). The
integrity of the HUVEC monolayer was assessed
microscopically. Before the experiment, cells were
washed twice with HEPES medium. 
At the start of the assay, 105 neutrophils were placed
in the upper compartment of the Transwell and
allowed to migrate for 1 hour at 37°C to a medium con-
taining chemokines (C5a or interleukin-8, both at 10
nM) added to the lower compartment. Migrated cells
were collected from the lower compartment and quan-
tified by flow cytometry in the presence of fixed
amounts of fluorescent beads. The percentage of
migrated cells was calculated as a fraction of the total
cell input, as follows: 
% of migrated cells = [(number of transmigrated cells
/number of beads)]/[(number of input cells/number of beads)]
x 100%.
Statistics
Results are presented as means ± SD unless other-
wise specified. Groups were compared using two-
tailed t test analysis. Differences were considered sta-
tistically significant if p<0.05.
Results
Characteristics of the granulocytes used for infusion:
phenotype and function
G-CSF/dexamethasone exposure changes the granulocyte
phenotype
Granulocytes obtained from granulocyte donors
(treated with G-CSF and dexamethasone) had lower
A. Drewniak et al.
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surface expression of the early activation markers
CD62L and CD16 (FcγRIIIb) compared to control cells
obtained from untreated donors, whereas the level of
CD64 (FcγRI) for prolonged activation was increased
(Figure 1A). More impressive upregulation was seen for
the neutrophil-specific NB1 antigen, CD177.22,23
CD66b expression on neutrophils from the granulo-
cyte donors was upregulated compared to that on con-
trol cells. On the other hand, surface expression of
CD11b and CD18, which are partially expressed in the
same compartments as CD66b, was similar. Surface
expression of additional adhesion molecules involved
in the process of transmigration (CD31, CD99, ICAM-
2, and PSGL-1) was unchanged (data not shown). The
tetraspanin molecule CD63, a marker of degranulation
of azurophil granules,15 was unchanged by prior in vivo
exposure of the donor to G-CSF/dexamethasone. 
Upon in vitro activation the upregulation of
CD11b/CD18, CD66b and CD63 was normal (data not
shown), which demonstrates the granulocytes’ normal
functional capacity to degranulate. No change in
expression was noted for the HLA class-II molecule. 
Granulocyte functions and interaction with
endothelial cells
Standard granulocyte functions, such as chemotaxis
and respiratory burst, were then investigated. No sig-
nificant differences were noted in the directed motility
in response to C5a, IL-8 or PAF, as compared to that of
the control cells (Online Supplementary Figure S1A). The
only difference was observed in the case of random
mobility of unstimulated cells (chemokinesis), which
was significantly enhanced in granulocytes from the
leukapheresis product (Online Supplementary Figure
S1A). The production of reactive oxygen species upon
neutrophil activation by various stimuli was normal
(Online Supplementary Figure S1B).
The interaction of neutrophils with endothelial cells
was investigated under various flow conditions. Rolling
of neutrophils over HUVEC monolayers and subse-
quent firm adhesion to these endothelial cells were
unaffected (Figures 1B and C), despite the 50% reduc-
tion in surface expression of CD62L (which is a major
molecule involved in cell-cell interactions between
granulocytes and endothelial cells) after G-CSF/dexam-
ethasone mobilization. The transmigration of granulo-
Figure 1. Effect of G-CSF/dexamethasone mobilization on the phenotype of granulocytes, and their interaction with endothelial cells. (A)
Expression of various surface antigens on granulocytes. CD11b, CD18, CD16, CD62L, CD64, CD63, CD66b and CD177 binding (all anti-
bodies were used at a concentration of 20 µg/mL) was compared on granulocytes isolated from healthy controls (open bars) and on cells
obtained from the leukapheresis products (black bars). Results are presented as mean fluorescent intensity (MFI) (mean ± SEM); statis-
tically significant differences (p<0.05) are indicated by an asterisk (*). The data represent results of experiments performed on granulo-
cytes obtained from five different granulocyte donors and ten healthy untreated controls. (B) Rolling capacity of neutrophils over stimu-
lated HUVEC under flow conditions. (C) Granulocyte adhesion to HUVEC stimulated by tumor necrosis factor-α. (D) Transmigration of gran-
ulocytes isolated from healthy controls (open bars) and leukapheresis products (black bars) through unstimulated HUVEC in response to
C5a or IL-8 (both at 10 nM). All data of B, C and D represent the mean ± SEM of the results of three independent experiments. 
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cytes through the endothelial cell layer induced by IL-8
or C5a was also comparable to that of control cells
(Figure 1D). 
Killing of micro-organisms
Because G-CSF and dexamethasone have been
described to have pronounced and contradictory effects
on the killing capacity of micro-organisms by neu-
trophils in vitro, especially on their fungicidal activity,24
we determined the capacity of granulocytes mobilized
for transfusion to kill a variety of different micro-organ-
isms, including E. coli, S. aureus, C. albicans and A. fumi-
gatus, which are all clinically relevant pathogens. All
micro-organisms were efficiently killed, and statistical-
ly significant differences were not observed between
control granulocytes and the mobilized granulocytes
(n=3-7 experiments in triplicate) (Online Supplementary
Figures S2A and S2B and data not shown).
Storage of granulocytes and concomitant changes in
phenotype and function: survival and decay in 
functional capacity 
Granulocyte concentrates collected by leukapheresis
are usually transfused as quickly as possible, preferably
within 6 hours. Longer storage periods are avoided
because of assumed poor granulocyte survival and
function.25,26 G-CSF/dexamethasone-mobilized granu-
locytes did, however, have a greatly prolonged life-
span during in vitro cultures, as determined by
annexinV-FITC/PI-staining and cell morphology, when
compared with control granulocytes (data not shown). 
After 24 hours of storage, the total white blood cell
counts of mobilized granulocyte concentrates had
decreased by approximately 5%. The viability of the
neutrophils was excellent, as determined by annexinV
binding (<5% apoptotic neutrophils, i.e. annexinV-
FITC+; data not shown) and cell morphology (Online
Supplementary Figures S3A and S3B).
Neutrophil functions (such as chemotaxis, adhesion,
respiratory burst and bactericidal and antifungal activi-
ty) all remained unchanged after storage of the granu-
locyte transfusion product for 24 hours (Figure 2 and
data not shown). Small changes were observed in surface
antigen expression after storage of the leukapheresis
product: CD62L expression decreased further during
storage. In addition, there was a slight increase in
CD11b and CD18 expression (which may be upregu-
lated from secretory vesicles or specific granules),
whereas the expression of CD63, a marker of azurophil
granule release, remained unchanged (data not shown).
Patients and granulocyte transfusions
Between December 2002 and October 2006, 16
patients fulfilled criteria for treatment with granulocyte
transfusions (curative group), 15 of whom had persist-
ent neutropenia due to treatment for pediatric cancer
and one of whom had a granulocyte dysfunction.18;27
Four children received pre-emptive granulocyte trans-
fusions during allogeneic or autologous SCT (Table 1),
of whom two had also received transfusions earlier in
a curative setting (#1 and #8). 
In the curative group, the first infusion of granulo-
cytes was administered after a prolonged period of
neutropenia (median, 21 days; range, 12-140), whereas
in the pre-emptive group granulocyte infusions were
started on the first day of expected neutropenia. The
median number of granulocyte infusions in the curative
group was three (range, 1-10) and in the pre-emptive
group six (range 4-9). Each infusion contained a medi-
an of 2×109 granulocytes/kg (range, 0.3-5.0×109/kg,
Table 2; additional information about other cells pres-
ent in the granulocyte concentrates are included in the
Online Supplementary Table S1). The increment in ANC
in the peripheral blood of the patients, measured 1 hour
after the granulocyte transfusion, was more than
1×109/L, and stayed above that level until 24 hours after
the infusion. Thereafter, the number decreased again in
most cases (Figure 3A). 
Clinical outcome
In the group treated curatively, the granulocyte trans-
fusions helped to control the infection in 11 of the 16
patients in whom antimicrobial therapy for >72 hours
had not resulted in any clinical improvement. The
increase in the number of circulating granulocytes was
followed by a decrease in CRP levels (Figure 3B). Eight of
the 11 patients with a proven Aspergillus species infection
showed clinical recovery, with galactomannan levels
becoming negative within 10 days after starting the
transfusions (Table 2). In three patients with Gram-nega-
tive infections (#6, #10 and #11) the infection resolved. 
Five patients died; two patients died 18 and 19 days
after initiation of transfusions from cerebral hemorrhage
and multiorgan failure, respectively (#5 and #7), and
three from rapidly progressive fungal infection less than
1 week after starting treatment with granulocyte transfu-
sions (#12, #14, #15); in two of these no increment in
neutrophils above 1×109/L at 1 hour after granulocyte
infusion was observed (Tables 1 and 2).
All children in the group treated pre-emptively sur-
vived their transplant procedure and showed no evidence
of disseminated infection. Three are alive and well more
than 1 year after SCT. One died 4.5 months after allo-
geneic SCT because of EBV-lymphoproliferative disease.
Discussion 
We studied the effects of G-CSF and dexamethasone
prestimulation of the donor, as well as the leukapheresis
and irradiation procedures on the viability, function, and
morphology of granulocytes used for transfusion of neu-
tropenic patients. We also assessed the clinical yield and
efficacy of the transfused cells in pediatric oncology
patients. 
The morphologic appearance of granulocytes from
granulocyte transfusion products and their basic func-
tions, such as respiratory burst, interaction with
endothelial cells, migration, and killing capacity, were all
normal. Although various immunological defects have
been reported to be caused by glucocorticoids in vivo and
in vitro,28 including decreased fungicidal activity of granu-
locytes,24 we did not observe these effects, perhaps
because of the concomitant administration of G-CSF.
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Table 1. Patients’ characteristics. 
Pt.n. Diagnosis Age (Chronic) Refractory to Therapy CMV Weight 
(years) infection (Kg)
Curative group
1 HLH 5 intestinal aspergillosis voriconazole HLH-2004 protocol induction phase neg 25
(Aspergillus fumigatus)
2 ALL 8 cutaneous aspergillosis voriconazole ALL-10 protocol: induction phase neg 29
(Aspergillus flavus)
3 HLH 21 pulmonary aspergillosis voriconazole post-SCT (day +28: double-unrelated cord blood pos 75
(Aspergillus fumigatus) [4/6 match either direction], Bu/Cy/VP16/ATG conditioning) 
4 BD 5 pulmonary aspergillosis amphotericin B pre-SCT (day –20 [10/10 match], neg 18
(Aspergillus fumigatus) → voriconazole Flud/Mabcampath/TBI conditioning)
5 MDS 2 pulmonary aspergillosis (HRCT vorirconazole post-SCT (day +35, rejection 1st unrelated cord blood: pos 13.5
changes & pos galactomannan ) Bu/Mel/Cy/ATG, day +14 2nd unrelated cord blood 
[5/6 match], without conditioning)
6* LAD 11 bilateral pneumonia ceftazidime immunodeficiency neg 31
(Pseudomonas aeruginosa)
7 Hepatoblastoma 7 bloodstream and ascites gentamycin, SIOPEL IV protocol first course neg 25
(Staphylococcus aureus flucloxacillin; 
and Candida albicans) amphotericin B & 
flucytosine
8 Neuroblastoma 3 sinusitis voriconazole after last course chemotherapy, neg 17
stage IV (Aspergillus fumigatus) 8 additional COJEC courses of chemotherapy before SCT
9 X-ALD, 6 pulmonary aspergillosis liposomal post-SCT (day +104, rejection BMT [10/10 match], neg 26
metabolic (Aspergillus fumigatus) amphotericin B Bu/Cy/ATG; day +39 rejection 2nd PBSCT same donor,
disease (Ambisome®) OKT3 conditioning; day +8 autologous BM rescue)
10 AML, relapse 13 perianal  cyclospori and ceftazadime, meronem, post-reinduction FLAG-daunosome pos 42.5
necrosis (Escherichia coli) tobramycin &  
surgical drainage
11 AML 1 portacath infection/necrosis ceftazadime, tobramycin; post-2nd FLAG-IDA induction therapy neg 9.0
& sepsis vancomycin, meronem;  
(Pseudomonas aeriginosa) surgical debridement
12 SAA 5 pulmonary aspergillosis liposomal amphotericin B immunosuppression neg 27
(Aspergillus fumigatus) (Ambisome®) (ATG, prednisolone, cyclosporine A)
→voriconazole
13 ALL, relapse 9 pulmonary aspergillosis meronem, voriconazole post-reinduction chemotherapy for relapsed ALL neg 52
(Aspergillus fumigatus) & surgery
14 Wilms’ tumor, 1 influenza A, CoNS liposomal amphotericin B post-intensive reinduction chemotherapy neg 8.6
relapse and possible Aspergillus, (Ambisome®) for relapsed Wilms’ tumor
HRCT →voriconazole
vancomycine
15 HLH 7 sepsis voriconazole plus  steroids, VP16, cyclosporine A; neg 20
(Candida albicans) flucytosine; meronem reactivation HLH due to EBV infection
16 ALL, relapse 5 pulmonary aspergillosis voriconazole & surgery; post-CLASP neg 20
(Aspergillus fumigatus) vancomycin, meronem
Pre-emptive granulocyte transfusions
17 X-CGD 10 liver abcesses linezolid BMT sibling [10/10 match], Bu/Cy/ATG neg 22
(Staphylococcus aureus)
18 ALL 13 mucormycosis amphotericin B BMT MUD [9/10 match: HLA-C mismatch], VP16/ATG/TBI pos 40
& surgery
19a (1) HLH 6 intestinal aspergillosis voriconazole unrelated cord blood [5/6 match: HLA-DR mismatch], neg 25
(Aspergillus fumigatus) BU/Cy/VP16/ATG
19b (1) voriconazole BMT MUD [9/10 match: HLA-DR mismatch], neg 25
VP16/Mabcampath/TBI
20 (8) Neuroblastoma sinusitis voriconazole autologous SCT neg 17.5
Stage IV 3 (Aspergillus fumigatus)
CMV: cytomegalovirus; HLH: hemophagocytic lympho-histocytosis; ALL: acute lymphoblastic leukemia; BD: Blackfan-Diamond; X-CGD: X-linked chronic granuloma-
tous disease; SAA: severe aplastic anemia; HRCT: high resolution; CT-scanning; SCT: stem cell transplantation; MUD: matched unrelated donor; Bu: busulfan; Cy:
cyclophosphamide; VP16: etoposide; ATG: anti-thymocyte globulin; Flud: fludarabine; TBI: total body irradiation; LAD: leukocyte adhesion deficiency; COJEC:
chemotherapy (vincristine, etoposide, carboplatin); FLAG: fludarabine and high-dose cytosine arabinoside; CLASP: high dose cytosine and L-asparaginase. 
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Table 2. Product infused, granulocyte counts after granulocyte transfusion and outcome. 
Pt. n. N. Day of G/kg infused G/L +1h G/L +1d G/L +2d GTX CRP  (mg/L: Galactomannan Current status
of GTX starting median (range) median median median stopped start→2GTX) (start → +10 days)
GTX (range) (range) (range) (day after 
(before SCT) initiation)
Curative group
1 2 No SCT 1.1 2.2 0.4 (0.1-2.6*) 5 307→54 pos (5)→neg See pre-emptive group: 
(1.7-3.3) (0.3-0.6) patient #19
2 4 No SCT 1.3 1.4  1.3 NT 12 285→120 pos (2)→neg Chemotherapy for B-ALL
(1.2-1.5) (0.24-1.8) (0.2-1.8)
3 5 +28 1.0 1.4 1.5 0.6 13 634→184 pos (2)→neg Died of pulmonary 
(0.5-1.2) (0.3-3.2) (0.2-2.6) (<0.1-1.1) insufficiency/
enterococci sepsis (+ 70d)
4 10 -20 2.1 2.6 1.0 <0.1 7 61→12 pos (?)→neg A&W, 100% donor
(0.8-2.7) (0.7-3.9) (0.1-2.4)
5 7 +35 3.3 1.3 0.8 0.1 18 (died) 287→181 pos (5)→pos (4) Multiple problems,
(2.5-4.1) (0.8-4.2) (0.1-2.1) (0.1-0.3) died of MOF 
(+ 21d after 2nd graft)
6# 4 No SCT 1.0 20.7 15.6 12.6 8 280→165 NA Ongoing infections but stable
(0.8-1.2) (17-28) (12.6-18.5) BMT successful at +320d
7 3 No SCT 2.1 2.5 1.3 0.6 5 342→273 NA Died of cerebral bleeding
(1.7-2.6) (0.9-2.1) (0.9-2.8) (+18d)
8 3 No SCT 2.7 6.8 4.3 1.0 8 248→95 pos (2.5)→? See pre-emptive group: 
(1.8-2.8) (5.8-7.8) (2.3-6.1) (0.4-1.7) patient #20
9 2 +104 1.8 3.6 3.0 1.2 5 329→34 pos (?)→neg Survived infection 
(1.7-1.9) (2.8-4.4) (2.2 -3.8) (0.4 -2.0) but died one year later
due to underlying disease
10 2 No SCT 2.0 1.5 2.0 0.6 5 257→61 NA Resolved underwent further 
(1.8-2.2) (1.4-1.6) (1.9-3.1) (0.5 -0.6) chemotherapy and BMT,
died due to acute GvHD
11 7 No SCT 0.22 3.8 2.0 0.9 10 286→36 NA Stable, further chemotherapy; 
(0.1-0.35) (2.0-12.2) (1.0- 6.6) (0-1.8) pre-emptive antibiotics
and GTX planned for future 
aplastic episodes
12 2 No SCT 1.0 0.1 <0.1 Not 4 (died) 325→196 Not evaluated Progressive infection,
(0.9-1.1) evaluated died in aplasia
13 6 No SCT 1.5 Not Not Not 13 157→86 Not evaluated Alive complete resolution
(0.3-3.0) evaluated evaluated evaluated of infection continued 
chemotherapy
14 1 No SCT 0.8 0.01 <0.1 Not evaluated 2 (died) 120→80 Not evaluated Died of progressive infection
15 2 No SCT 1.7 2.1 1.4 Not evaluated 5 (died) 410→327 NA Died due to respiratory
(1.3-2.0) (1.1-3.1) (0.9-2.7) insufficiency and progressive
underlying disease
16 3 No SCT 2.6 0.4 2.6  Not evaluated 8 264→47 Pos (7.5)→neg Aspergillus resolution
(0.7-3.7) ( 0.1-0.7) (0.4-9.4) post-surgery. BMT; 
died of cardiac failure
Pre-emptive group
17 5 -3 2.3 1.2 0.5 0.1 12 70→<7 NA A&W
(1.2-3.5) (1.1-3.1) (0.2-1.8) (<0.1-0.1)
18 9 1 1.0 0.6 0.2 <0.1 26 <7a NA A&W, 100% donor, cured 
(0.7-1.7) (0.4-0.6) (<0.1-0.3) from GvHD III (skin, liver)
19a (1) 9 -1 2.7 9.3 5 2 34 <7a NA Engrafted; HLH flare 
(2.3-3.4) (1.6-16.9) (1.7-9.9) (<0.1-4.7) associated with adenovirus 
infection
19b (1) 6 -7 2.0 6.3 5.2 0.3 26 <7a NA 100% donor, GvHD gr.IV 
(1.3-2.3) (2.9-9.9) (0.23-6.4) (0.1-2.5) (liver). Died of EBV-LPD 
(+150d)
20 (8) 4 +5 3.0 3.2 0.2 0.2 14 11→43 NA A&W
(1.9-5.0) (2.7-3.7) (<0.1-0.3) (<0.1-0.3)
GTX: granulocyte transfusion; SCT: stem cell transplantation; G: granulocyte (1x109); *includes some autologous reconstitution; NT: not tested; NA: not applicable; aCRP at
start, #LAD with pre-existing leukocytosis, mainly of dysfunctional neutrophils. A&W = alive and well. EBV-LPD=EBV-associated lymphoproliferative disease.
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Thus, granulocytes given to the patients were fully capa-
ble of fighting fungal infections as well as bacterial ones.
Minor changes were observed in surface antigen
expression, possibly caused by the prior administration
of G-CSF and dexamethasone to the donor25,29,30 or by the
leukapheresis procedure. CD62L expression was the sur-
face antigen most affected by the mobilization and sub-
sequent leukapheresis procedures. This member of the
selectin family has been described to be required for the
initial contact with the endothelium in post-capillary
venules prior to extravasation.31,32 However, we observed
that rolling over and firm adhesion to HUVEC in vitro,
under flow conditions, were unchanged despite the
greatly reduced levels of CD62L expression. The expres-
sion of other adhesion molecules, such as CD31, CD11b
and CD18, remained unchanged. The unaltered granulo-
cyte-endothelial cell interactions may be due to the
strongly increased expression of CD177 on the mobi-
lized granulocytes. CD177, also known as human neu-
trophil antigen 2a (HNA2a or NB1), has recently been
reported to function as a ligand for endothelial CD31
(PECAM-1), thus playing an important role in the adhe-
sion and transmigration of neutrophils through endothe-
lial cell monolayers.33
Another highly complex process, directed motility or
chemotaxis, remained unaffected by the in vivo and in
vitro manipulations required for the preparation of a gran-
ulocyte transfusion product. Only a minor enhancement
of random migration (chemokinesis) was observed. This
suggests a certain degree of pre-activation of the cells,
which was probably due to the leukapheresis procedure,
because the chemokinesis of granulocytes isolated direct-
ly from the blood of the same donors was comparable
with that of control granulocytes (data not shown). 
The life-span of granulocytes obtained from granulo-
cyte transfusion donors is prolonged in in vitro cultures as
well as in vivo.2,13,14,26,30,34 Given the inherent association of
apoptosis with functional decay during storage35 and the
possible influence on survival of G-CSF in vivo, we tested
the effects of 24-hour storage of the granulocyte concen-
trates. Total white blood cell counts within the granulo-
cyte transfusion bags were maintained at levels of more
than 95% of the starting counts, with an equally high
viability. The cell morphology of mobilized granulocytes
after 24 hours of storage showed no differences from
that of fresh control cells on cytospins and electron
microscopy pictures, and there were no signs of apopto-
sis or cell activation. Furthermore, we did not detect any
release of elastase or IL-8 from the granulocytes into the
fluid of the bags during storage (data not shown). The
release of pro-inflammatory cytokines, including IL-8,
may potentially cause adverse reactions after a granulo-
cyte transfusion, but the levels of IL-8 in the bag of the
granulocyte concentrates appeared not to increase before
36-48 hours of storage, and then rose up to 72 hours – as
was also shown by others.36,37
Figure 2. Effect of storage on granulocyte chemotaxis.
Chemotaxis of granulocytes purified from healthy controls and
from freshly prepared and stored leukapheresis products.
Chemotaxis in response to C5a (10 nM), IL-8 (10 nM) and PAF
(100 nM) was measured in granulocytes isolated from the granu-
locyte concentrates at time 0 (black bars) and after storage for 24
hours (gray bars). Results are presented as the extent of chemo-
taxis (in RFU). The results are from eight separate experiments
(mean ± SEM). Statistically significant differences (p<0.05) are
indicated by an asterisk (*). 
Figure 3. Granulocyte infusion and clinical response. (A) Number
of granulocytes present in the blood of patients at 1 hour, 1 day
and 2 days after granulocyte transfusion. Results are presented as
a median with range (for more details see also Table 2). (B)
Absolute neutrophil count (ANC) and c-reactive protein (CRP) lev-
els during treatment with granulocyte transfusions in a represen-
tative patient (arrows indicate the moment of granulocyte transfu-
sion, GTX). The third leukapheresis procedure resulted in a poor
product (0.2x109 granulocytes/kg), which explains the lack of
increment in the number of circulating granulocytes. 
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One of the first functional abnormalities that occurs in
stored granulocytes is a reduction of their motility. In our
study, mobilized neutrophils from granulocyte concen-
trates retained the ability to undergo chemotaxis in
response to a panel of chemoattractants (IL-8, C5a, PAF)
after storage at ambient temperature, which is in agree-
ment with the observations of Leavey et al. and those of
Hubel et al. on the effects of storage at room temperature
or 10°C, respectively, for 24h.38,39,43
Another important issue is whether stored granulo-
cytes retain antifungal activity. Individuals with severe-
ly prolonged neutropenia or neutrophil dysfunction
have an increased risk of developing fungal infections.1
Granulocytes from leukapheresis products stored at
ambient temperature retained the ability to kill oppor-
tunistic fungi efficiently (data not shown). Hubel et al.
also described that granulocytes stored for 24h at 10°C
had more than 80% efficacy in killing fungal pathogens,
as compared to the baseline killing.38 Thus, we may
infer that granulocytes from G-CSF/dexamethasone-
mobilized donors, despite some minor phenotypic
changes, can still be used therapeutically for up to 24
hours after leukapheresis. This possibility of using
stored granulocytes could be particularly relevant in
small pediatric patients, since it would allow concen-
trates to be split for other patients. The in vivo yield and
efficacy of stored granulocytes now need to be evaluat-
ed in a small pilot study.
The final part of this study was carried out to assess
the yield and efficacy of granulocyte transfusions in
severely neutropenic children suffering from life-threat-
ening infections unresponsive to standard treatment.
The clinical response (e.g. remarkable decrease in CRP,
and galactomannan becoming negative) after the start
of granulocyte transfusions suggests their in vivo effica-
cy. Once infused, granulocytes remained detectable in
the blood for more than 24 hours, apart from in three
patients, two of whom died of rapidly progressive
aspergillosis. 
In this study, granulocyte transfusions seemed to ben-
efit at least 70% of the patients in the group treated cura-
tively, as infections were eradicated or controlled in 11
out of 16 patients in this group. This result is superior to
that in the past in similar patients who did not receive
granulocyte transfusion treatment, and is in agreement
with more recently published reports.3,5,40-42 Prophylactic
granulocyte transfusion has already been reported to be
beneficial in such patients.8,9,40,43,44 None of our patients
treated pre-emptively showed progression of prior low-
grade (fungal) infection during the period of neutropenia
after SCT conditioning. Our experience with a small
number of patients precludes firm conclusions, although
all the indication are that these patients do indeed bene-
fit from granulocyte transfusions. 
Taken together, our data show that G-CSF/dexametha-
sone-mobilized granulocytes have a completely intact
ability to respond to signs of infection, migrate towards
an ongoing infection and kill invading pathogens, as
shown by various in vitro assays and a small clinical in
vivo study. 
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